cobimetinib
15 products
11 abstracts
1 target
Target
MEKAbstract
Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.Org: Henry Ford Cancer Hospital, Northwestern University - McGaw Medical Center,
Abstract
Beacon: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer.Org: The Royal Women’s Hospital, Cancer Immunology Research,
Abstract
Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.Org: Deparment of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Immunotherapy and Cell Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, IRCCS Istituto Oncologico di Bari Giovanni Paolo II, Oncology Department, Institute of Dermatology, Catholic University Fondazione Policlinico Universitario, Medical Oncology Unit, Department of Oncology, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro,
Abstract
Nab-paclitaxel and gemcitabine (modified) in combination with oral cobimetinib and encorafenib following FOLFIRINOX in patients with metastatic G12D and G12V pancreatic cancer.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL, Sylvester Cancer Center,
Abstract
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.Org: Emory University School of Medicine and Winship Cancer Institute, Investigational Drug Branch, Winship Cancer Institute of Emory Univeristy,
Abstract
A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Stanford University School of Medicine, Palo Alto, CA, Henry Ford Cancer Institute, Detroit, MI,
Abstract
Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.Org: The University of Arizona, Tucson, AZ, University of Arizona Cancer Center, University of Arizona, University of Arizona of Pharmacy, Department of Pharmacy Practice and Science,
Abstract
Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.Org: Rush University Medical School, FibroFighters Foundation, Nagourney Cancer Institute, FibroFighters.org, Rush University Medical Center,
Abstract
A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.Org: Sunnybrook Hospital, Royal Victoria Hospital/Glen Site/Cedar Cancer Centre, Department of Surgery, University of Ottawa-Ottawa General Hospital, Jewish General Hospital Stroll Cancer Prevention Centre, Lady Davis Institute, McGill University,
Abstract
Efficacy of vemurafenib based regimens in colorectal cancer: A systematic review of clinical trials.Org: New York Medical College - Saint Michael's Medical Center, Saint Michael's Medical Center, St. Michael's Medical Ctr, Reg Cancer Ctr At St Michael's Medical Ctr,
Product
belvarafenib + cobimetinibProduct
COTELLIC + VemurafenibProduct
BRAF & MEK inhibitorsProduct
targeted therapiesProduct
vemurafenib plus cobimetinibProduct
BRAF±MEK inhibitorsProduct
vemurafenib and cobimetinibProduct
BRAF/MEK inhibitorsProduct
cobimetinib, atezolizumab